{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:30:32Z","timestamp":1790688632071,"version":"4.1.0"},"reference-count":83,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Uveal melanoma (UM) is the most common primary ocular tumour in adults. Despite good local control of the primary tumour with current methods, survival after the development of metastasis has remained poor over the last 30\u2009years. After cutaneous melanoma, UM is the most common type of melanoma, and an ongoing debate exists regarding whether these conditions should be considered separate entities, particularly in the context of targeted therapy, where many of the initial trials for patients with metatatic cutaneous melanoma excluded metastatic UM. This paper will review the recent and ongoing investigations designed to validate systemic targeted therapy and immunotherapy in patients with metastatic UM and suggests ways in which these developments may affect management of UM by ophthalmologists in the near future.<\/jats:p>","DOI":"10.1111\/ceo.12688","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T06:02:34Z","timestamp":1448431354000},"page":"509-519","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review"],"prefix":"10.1111","volume":"44","author":[{"given":"Amanda YL","family":"Goh","sequence":"first","affiliation":[{"name":"School of Medicine University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Layton","sequence":"additional","affiliation":[{"name":"School of Medicine University of Queensland Brisbane Queensland Australia"},{"name":"Gallipoli Medical Research Institute Brisbane Queensland Australia"},{"name":"Ophthalmology Department Greenslopes Private Hospital Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.133"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11057"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.255"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.023"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"360136","DOI":"10.1155\/2010\/360136","article-title":"Genetics of uveal melanoma and cutaneous melanoma: two of a kind?","volume":"2010","author":"Bosch T","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"e_1_2_7_7_1","first-page":"1230","article-title":"Ocular melanoma: an overview of the current status","volume":"6","author":"Jovanovic P","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.046"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18","volume":"119","author":"Diener\u2010West M","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72432-8"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archopht.1995.01100030071024","article-title":"Transpupillary thermotherapy in choroidal melanomas","volume":"113","author":"Oosterhuis JA","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827f65c8"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0659"},{"key":"e_1_2_7_14_1","first-page":"130","article-title":"The gamma knife in ophthalmology. Part One\u2010\u2010Uveal melanoma","volume":"116","author":"Wygledowska\u2010Promienska D","year":"2014","journal-title":"Klin Oczna"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002341-200109000-00010"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S28863"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.069823"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00182-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0348-y"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130103030"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.5.670"},{"key":"e_1_2_7_22_1","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"Cruz F","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000130006.46885.a0"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602598"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1750"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2401"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.017"},{"key":"e_1_2_7_28_1","article-title":"The DecisionDx\u2010UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma","volume":"5","author":"Harbour JW","year":"2013","journal-title":"PLoS Curr"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO;2-J"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194472"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2296"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.417"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0946"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14550"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2011-100156"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e32835d0efb"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035295"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.418"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10427"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000584"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07586"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2145"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.555"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029622"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-22"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1470-z"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.9030","article-title":"Phase I dose\u2010escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma","volume":"32","author":"Piperno\u2010Neumann S","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3227"},{"key":"e_1_2_7_50_1","first-page":"1","article-title":"Insulin\u2010like growth factor\u20101 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target","volume":"43","author":"All\u2010Ericsson C","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0322"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283507ffd"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2012.09.003"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31824bd256"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1106"},{"key":"e_1_2_7_56_1","unstructured":"ChattopadhyayC WoodmanSE EsmaeliB GrimmEA.2012.Targeting IGF\u20101R in uveal melanoma cells. ARVO abstract \u2013 3396 \u2013 A589."},{"key":"e_1_2_7_57_1","first-page":"2591","article-title":"New therapeutic agents in uveal melanoma","volume":"32","author":"Velho TR","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000125"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4755"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0534"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328358b373"},{"key":"e_1_2_7_62_1","article-title":"A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma","volume":"26","author":"Chan KR","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12304"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_7_65_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e19032","article-title":"Predictable clinical responses to sorafenib in stage IV uveal melanoma","volume":"30","author":"Kaempgen E","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12432"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048787"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1529"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9966-3"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1089-0"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt376"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"e_1_2_7_76_1","first-page":"1219","article-title":"Phase II study evaluating ipilimumab monotherapy in the first\u2010line treatment of adult patients with metastatic uveal melanoma (MUM): the GEM1 trial [Abstract]","volume":"27","author":"Piulats Rodriguez JM","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1606"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21224"},{"key":"e_1_2_7_82_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","article-title":"A phase II study of interleukin\u20102 and lymphokine\u2010activated killer cells in patients with metastatic malignant melanoma","volume":"7","author":"Dutcher JP","year":"1989","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90266-5"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fceo.12688","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.12688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T14:23:47Z","timestamp":1748701427000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.12688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,11]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/ceo.12688"],"URL":"https:\/\/doi.org\/10.1111\/ceo.12688","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,11]]},"assertion":[{"value":"2015-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}